Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rockwell's Triferic OK'd, but without ESA-sparing use

This article was originally published in Scrip

Executive Summary

Rockwell Medical revealed on 26 January it had won approval from the FDA to market Triferic (ferric pyrophosphate) as a replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease.

You may also be interested in...



Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Related Companies

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel